Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1432-0843
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia ; day:8 ; month:1 ; year:2021 ; pages:1-11
Cancer chemotherapy and pharmacology ; (8.1.2021), 1-11

Urheber
Kang, Dongwoo
Ludwig, Elizabeth
Jaworowicz, David
Huang, Hannah
Fiedler-Kelly, Jill
Cortes, Jorge
Ganguly, Siddhartha
Khaled, Samer
Krämer, Alwin
Levis, Mark
Martinelli, Giovanni
Perl, Alexander
Russell, Nigel
Abutarif, Malaz
Choi, Youngsook
Yin, Ophelia
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s00280-020-04204-y
URN
urn:nbn:de:101:1-2021020820414818391266
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:38 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Kang, Dongwoo
  • Ludwig, Elizabeth
  • Jaworowicz, David
  • Huang, Hannah
  • Fiedler-Kelly, Jill
  • Cortes, Jorge
  • Ganguly, Siddhartha
  • Khaled, Samer
  • Krämer, Alwin
  • Levis, Mark
  • Martinelli, Giovanni
  • Perl, Alexander
  • Russell, Nigel
  • Abutarif, Malaz
  • Choi, Youngsook
  • Yin, Ophelia
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

Management of relapsed-refractory diffuse large B cell lymphoma

Management of relapsed-refractory diffuse large B cell lymphoma

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

Verbundene Objekte